PATENT CLAIM ANALYSIS

Application Number: 15960205
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "006900"]

Abstract:
Disclosed are a composition for preventing or treating diabetes, disbesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels.

Claim (Index 4):
The method of  claim 3 , wherein the oxyntomodulin analog comprises the amino acid sequence of SEQ ID NO: 25.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.74648
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15086499', '14126914', '15636160', '15846395', '15315020']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.783789766083893
- 35 USC 102 Novelty (BERT): 0.5427499757352822
- Combined Prediction Score: 0.7596857870490319
- Mean Citation Score: 365.745042
- Max Citation Score: 372.91638
- Similarity Product: 315.1503826251161

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test